The HeraBEAT foetal heart rate monitor. Source: HeraMED
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • HeraMED (HMD) partners with e-Lōvu Health to supply its HeraCARE remote pregnancy monitoring technology to customers in the United States
  • The companies strike a binding term sheet that will see the HeraMED supply 1000 kits to expectant mothers at e-Lōvu’ partner healthcare provider sites
  • During the first year, e-Lōvu will pay HeraMED about US$550,000 (A$787,000) for the technology and a HeraCARE license
  • The first e-Lōvu site is expected to launch by the end of the year, with full deployment expected in the next six to twelve months
  • Shares in HeraMED are up 25 per cent to 16 cents per share at 10:17 am AEST

Pregnancy care tech specialist HeraMED (HMD) has partnered with e-Lōvu Health to supply its HeraCARE remote pregnancy monitoring technology to customers in the United States.

The companies have signed a binding term sheet that will see HeraMED supply 1000 kits to expectant mothers at e-Lōvu’ partner healthcare provider sites.

The kits to be provided under the deal include the HeraBEAT foetal heart rate monitor and Bluetooth-connected blood pressure cuffs with HeraCARE connectivity, which allow future mothers to monitor their pregnancies.

During the first year of the deal, e-Lōvu will pay HeraMED about US$550,000 (A$787,000) for the technology and a HeraCARE license.

However, this is subject to e-Lōvu Health securing the required funding, which is expected at the end of the third quarter this year.

The first e-Lōvu site is expected to launch by the end of the year, with full deployment expected in the next six to twelve months.

Following the initial period, the companies plan to enter a long-term strategic partnership.

HeraMED CEO and Cofounder David Groberman said he saw great potential in the partnership.

“The deal clearly validates the advantages of our technology and business model and officially launches our commercialisation into the United States market,” Mr Groberman said.

Shares in HeraMED were up 25 per cent to 16 cents per share at 10:17 am AEST.

HMD by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: Worst session in 6 weeks for bourse | July 25, 2024

The ASX200 closed in the red, down nearly 1.3% to 7,861.2 points. All sectors made losses…
The Market Online Video

ASX Market Update: Index falls hard on company earnings | July 25, 2024

The ASX200 has been trading down nearly 1.2% to 7,870 points. Overnight, earnings reports from US…
Saccharomyces cerevisiae yeast, 3D illustration.

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

Biotech company Tissue Repair Ltd (ASX:TRP) has seen its share price rise more than 30% on news it had gained TGA (Therapeutic
Closeup graph of Binary option for trading platform

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

Tech sector companies Ovanti Ltd and Brainchip Holdings Ltd joined Lake Resources Ltd and VHM Ltd…